Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $229

Benzinga Newsdesk www.benzinga.com Positive 51.4%

Neg 0% Neu 0% Pos 51.4%

Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $224 to $229.